Table II.
Demography and clinical characteristics of the preMG-PD group.
| First author, year | Sex/Age, years | MG antibodies | Ocular symptoms | Dysphagia | Dysarthria | Head drop | MG treatment | Comorbidities | Interval | PD symptoms | PD treatment | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iwasaki, 1988 | F/62 | AChR: P | Y | N | N | N | Pyd | NR | 2 months | R + RT + BK | None | (7) |
| Levin, 2003 | F/68 | AChR: P | Y | N | N | N | Pyd, AZA | NR | 3 years | R + restlessness | LD | (8) |
| Neuman, 2014 | M/72 | AChR: P | Y | N | N | N | Pyd | NR | 4 years | RT + R + BK | NO | (12) |
| Ozer, 2016 | M/67 | NR | N | N | Y | N | Pyd | Chronic subdural hematoma | 16 months | BK | LD, benserazide | (27) |
| Alshaikh, 2021 | M/70 | AChR: P | Y | N | N | Y | NR | Thyroid disease | 8 years | NR | NR | (4) |
| Alshaikh, 2021 | M/66 | AChR: P | Y | Y | Y | N | NR | Neuropathy, thyroid disease, vitamin B12 deficiency, childhood polio | 1 year | NR | NR | (4) |
| Alshaikh, 2021 | M/66 | AChR: P | Y | Y | Y | Y | NR | Neuropathy, thyroid disease, vitamin B12 deficiency | 8 years | NR | NR | (4) |
| Alshaikh, 2021 | F/85 | AChR: P | Y | Y | Y | Y | NR | Neuropathy | 4 years | NR | NR | (4) |
| Alshaikh, 2021 | M/49 | SN | Y | Y | Y | N | NR | Thyroid disease | 22 years | NR | NR | (4) |
| Alshaikh, 2021 | F/55 | NR | Y | Y | N | N | NR | Neuropathy | 19 years | NR | NR | (4) |
| Alshaikh, 2021 | M/59 | SN | N | Y | N | N | NR | Neuropathy, thyroid disease, Lyme disease | 10 years | NR | NR | (4) |
| Alshaikh, 2021 | M/52 | NR | Y | N | N | N | NR | Thyroid disease, vitamin B12 deficiency | 20 years | NR | NR | (4) |
F, female; M, male; PD, Parkinson's disease; R, rigidity; RT, resting tremor; BK, bradykinesia; LD, levodopa; SN, seronegative; MG, myasthenia gravis; AChR, acetylcholine receptor; MuSK, muscle-specific kinase; NR, not reported; P, positive; Y, yes; N, No.